WVE News and Press, Wave Life Sciences Ltd.

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is...

2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...

2024-05-15 14:11:35 ET More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q1 2024 Earnings Call Transcript Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript Wave Life Sciences ...

2024-05-15 07:00:05 ET Tiago Fauth from Wells Fargo issued a price target of $11.00 for WVE on 2024-05-15 05:53:00. The adjusted price target was set to $11.00. At the time of the announcement, WVE was trading at $5.84. WVE currently trades -24.58% versus its 52 week hig...

2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...

2024-05-09 14:53:01 ET Wave Life Sciences Ltd. (WVE) Q1 2024 Earnings Conference Call May 09, 2024 08:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-...

2024-05-09 07:41:48 ET More on Wave Life Sciences Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche Seeking Alpha’s Quant Rating on Wave Life Sciences Read the full article on Seeking Alpha For further details see: Wave Life Sciences ...

RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, ...

2024-05-09 07:11:34 ET More on Wave Life Sciences Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche Read the full article on Seeking Alpha For further details see: Wave Life Sciences names Erik Ingelsson as chief scientific officer

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Off...